

PERSPECTIVE

# Functional Selectivity of GPCR Ligand Stereoisomers: New Pharmacological Opportunities

Roland Seifert and Stefan Dove

Department of Pharmacology, Medical School of Hannover, Hannover, Germany (R.S.); and Department of Pharmaceutical and Medicinal Chemistry II, University of Regensburg, Regensburg, Germany (S.D.)

Received October 21, 2008; accepted October 21, 2008

## ABSTRACT

It is now well established that any given ligand for a G-protein-coupled receptor (GPCR) does not simply possess a single defined efficacy. Rather, a ligand possesses multiple efficacies, depending on the specific down-stream signal transduction pathway analyzed. This diversity may be based on ligand-specific GPCR conformations and is often referred to as “functional selectivity.” It has been known for a century that stereoisomers of catecholamines differ in their potency and, in some systems, also in their efficacy. However, the molecular basis for efficacy differences of GPCR ligand stereoisomers has remained poorly defined. In an elegant study published in this issue of *Molecular Pharmacology*, Woo et al. (p. 158) show that stereoisomers of the  $\beta_2$ -adrenoceptor selective agonist fenoterol differentially activates  $G_s$ - and  $G_i$ -proteins in native rat cardiomyocytes. This study is so important because it is the

first report to show that even the subtle structural differences within a ligand stereoisomer pair are sufficient to discriminate between GPCR conformations with distinct G-protein coupling properties. The study highlights of how important it is to examine the “more active” (eutomer) and the “less active” (distomer) stereoisomer to understand the mechanisms of action and the cellular effects of GPCR ligands. The study by Woo et al. will ignite a renaissance of the analysis of ligand stereoisomers, using sensitive pharmacological and biophysical assays. The available literature supports the notion that meticulous analysis of ligand stereoisomers is a goldmine for understanding mechanisms of GPCR activation, analysis of signal transduction pathways, development of new therapies for important diseases, and drug safety.

The two-state model assumes that GPCRs exist in an inactive (R) state and an active ( $R^*$ ) state. Binding of an agonist to GPCR stabilizes the active  $R^*$  conformation in the receptor, allowing it to promote GDP/GTP exchange in G-proteins and subsequent activation (or inhibition) of cellular effector systems (Gether and Kobilka, 1998; Seifert and Wenzel-Seifert, 2002). Partial agonists exhibit lower efficacy than full agonists at stabilizing the  $R^*$  state and, accordingly, are less efficacious at promoting G-protein activation. However, during the past decade, it has become increasingly clear from

pharmacological and biophysical studies that agonists actually possess multiple efficacies, depending on the specific G-protein to which the GPCR is coupled and the particular down-stream signal transduction pathway analyzed. Thus, instead of a single active  $R^*$  state, multiple ligand-specific active GPCR conformations ( $R^{*1}$ – $R^{*n}$ ) may exist (Fig. 1). Classic pharmacological concepts did not predict this diversity and complexity in agonist action, which is currently often referred to as “functional selectivity.” This issue has been the subject of a number of excellent recent reviews by leading groups (Perez and Karnik, 2005; Galandrin et al., 2007; Kenakin, 2007; Kobilka and Deupi, 2007; Milligan et al., 2007; Neubig, 2007; Urban et al., 2007; Lohse et al., 2008).

Supported by the Deutsche Forschungsgemeinschaft (Graduiertenkolleg 760 “Medicinal Chemistry: Molecular Recognition–Ligand–Receptor Interactions” to R.S. and S.D. While working at the University of Kansas (Lawrence, KS), the  $\beta_2$ AR work of R.S. was supported by grants 005140Z and 0450120Z from the Heartland Affiliate of the American Heart Association.

Article, publication date, and citation information can be found at <http://molpharm.aspetjournals.org>.

doi:10.1124/mol.108.052944.

Please see the related article on page 158.

## The $\beta_2$ AR, a Dually $G_s$ - and $G_i$ -Coupled GPCR

On this conceptual background, the study by Woo et al. (2008), published in this issue of *Molecular Pharmacology*,

**ABBREVIATIONS:** GPCR, G-protein-coupled receptor; AR, adrenergic receptor; TM, transmembrane domain;  $G_i$ , inhibitory G-protein of adenylyl cyclase;  $G_s$ , stimulatory G-protein of adenylyl cyclase;  $G_q$ , stimulatory G-protein of phospholipase C.

adds an additional layer of complexity to the topic of functional selectivity. Together with the light receptor, rhodopsin, the  $\beta_2$ AR is the best-studied GPCR in terms of functional domains, ligand-receptor interactions, G-protein and effector coupling, physiological function (Gether and Kobilka, 1998; Rohrer and Kobilka, 1998), and high-resolution crystal structures (Cherezov et al., 2007; Rosenbaum et al., 2007). The catecholamines (–)-epinephrine, a hormone produced by the adrenal medulla, and (–)-norepinephrine, a neurotransmitter, are the endogenous ligands of the  $\beta_2$ AR. The  $\beta_2$ AR is a classic  $G_s$ -coupled GPCR, triggering activation of adenylyl cyclase with subsequent cAMP production. In 1995, Xiao et al. made the very intriguing observation that pertussis toxin, ADP-ribosylating  $G_i$ -protein  $\alpha$ -subunits and, therefore, uncoupling GPCRs from  $G_i$ , enhanced  $\beta_2$ AR-mediated positive inotropic effects in isolated rat cardiomyocytes. These data suggested that in addition to  $G_s$ , the  $\beta_2$ AR also couples to  $G_i$ -proteins in native systems. Then, in 2003, Xiao et al. noted that the positive inotropic responses toward most  $\beta_2$ AR agonists such as zinterol, salbutamol (albuterol), and procaterol were enhanced by pertussis toxin pretreatment, whereas the effects of fenoterol were not affected. These findings were the first indication that fenoterol may stabilize a unique  $\beta_2$ AR conformation promoting a distinct pattern of G-protein activation.

#### Different Efficacies of GPCR Ligand Stereoisomers


It has been known for a century that the naturally occurring (–)-stereoisomer of epinephrine constricts blood vessels more potently than (+)-epinephrine (Cushny, 1908). Since then, a large number of studies has elaborated the concept that (–)-stereoisomers of catecholamines bind to adrenergic receptors with higher affinity and activate the receptors with higher potency than the corresponding (+)-stereoisomers. This concept has recently been covered in an excellent review (Patil et al., 2008).

Intriguingly, some studies reported not only differences in affinity/potency between stereoisomers but also differences in efficacy. In particular, (–)-norepinephrine induces a slow conformational change in purified  $\beta_2$ AR,

whereas (+)-norepinephrine is inactive in this respect (Swaminath et al., 2004). In addition, in the presence of ITP or XTP, but not in the presence of GTP, (+)-isoproterenol is less efficacious than (–)-isoproterenol at activating adenylyl cyclase by a  $\beta_2$ AR- $G_s\alpha$  fusion protein (Seifert et al., 1999). There are also striking differences in the efficacies of (–)- and (+)-isoproterenol at stabilizing high-affinity agonist binding (i.e., ternary complex formation) in a constitutively activated  $\beta_2$ AR mutant ( $\beta_2$ AR<sub>CAM</sub>) (Seifert et al., 2001). Moreover, differences in efficacy between (–)- and (+)-epinephrine were observed in native tissues and cell membranes (Kim et al., 1981; Patil et al., 1996). Beyond catecholamines, dexmedetomidine is a partial  $\alpha_{2A}$ -adrenergic receptor agonist, whereas the other stereoisomer, levomedetomidine, acts as inverse agonist [i.e., a ligand that stabilizes the inactive (R) state of the GPCR] (Jansson et al., 1998). Furthermore, stereoisomers of chiraprodifens, a new class of potent synthetic histamine  $H_1$ -receptor agonists, exhibit striking species-specific pharmacological properties at the human, rat, guinea pig, and bovine  $H_1$ -receptor (Strasser et al., 2008). Together, these data provide the basis for the concept that stereoisomers of a given ligand stabilize functionally distinct GPCR conformations.

#### Differential $G_s$ - and $G_i$ -Protein Activation by Fenoterol Stereoisomers

The analysis of the unique effects of fenoterol in cardiomyocytes was complicated by the fact that the compound possesses two chirality centers, yielding four fenoterol stereoisomers, referred to as (*R,R*)-, (*R,S*)-, (*S,R*)-, and (*S,S*)-fenoterol (Jozwiak et al., 2007). The study of Woo et al. (2009) focused on the analysis of (*R,R*)- and (*S,R*)-fenoterol and the fenoterol derivatives (*R,R*)-methoxyfenoterol and (*S,R*)-methoxyfenoterol in isolated rat cardiomyocytes. The compounds studied exhibit selectivity for the  $\beta_2$ AR relative to the  $\beta_1$ AR, and the *R,R* stereoisomers possess considerably higher affinity for the  $\beta_2$ AR than the *S,R* stereoisomers (Jozwiak et al., 2007). (*R,R*)- and (*S,R*)-fenoterol are similarly efficacious at increasing contractility of the cardiomyocytes via the  $\beta_2$ AR. Most strikingly, pertussis toxin shifts the contraction concentration-response curve for (*S,R*)-fenoterol to the left, whereas the stimulatory effects of (*R,R*)-fenoterol are unaffected by the toxin. Moreover, (*S,R*)-fenoterol stimulates extracellular signal-regulated kinase phosphorylation in a pertussis toxin-sensitive fashion, whereas the stimulatory effects of the corresponding *R,R* stereoisomers are pertussis toxin-insensitive. These data indicate that (*R,R*)-fenoterol activates only  $G_s$ -proteins, whereas (*S,R*)-fenoterol activates both  $G_i$  and  $G_s$  (Fig. 1). This interpretation is supported by G-protein photoaffinity-labeling experiments. In particular, (*R,R*)-fenoterol is more effective at stimulating the incorporation of [ $\gamma$ - $^{32}$ P]GTP azidoanilide into  $G_s\alpha$  than (*S,R*)-fenoterol, whereas only (*S,R*)-fenoterol stimulates photoaffinity labeling of  $G_{i\alpha_2}$ .  $G_{i\alpha_2}$  is the predominant pertussis toxin-sensitive G-protein in the heart. Thus, the previously noted PTX-insensitivity of the effects of racemic fenoterol in cardiomyocytes (Xiao et al., 2003) could be explained by the fact that the higher potency of (*R,R*)-fenoterol at the  $\beta_2$ AR for  $G_s$  masked the effect of (*S,R*)-fenoterol, possessing a lower potency for  $G_s$  and  $G_i$  (Fig. 1). These data show that it is sometimes misleading to use the evaluative terms eutomer and distomer (introduced by E. J. Ariens for the more and



**Fig. 1.** Differential activation of the  $\beta_2$ AR, G-proteins, and signal transduction pathways by (*R,R*)-fenoterol and (*S,R*)-fenoterol in cardiomyocytes. The scheme was developed on the basis of the data by Woo et al. Please note that (*R,R*)-methoxyfenoterol and (*S,R*)-methoxyfenoterol exhibit different G-protein specificity than the corresponding fenoterol stereoisomers. AC, adenylyl cyclase; ERK extracellular signal-regulated kinase; PTX, pertussis toxin.

less potent stereoisomer, respectively), which are by definition based on a particular affinity and/or potency. However, the distomer may actually possess more interesting and important pharmacological properties than the eutomer (Fig. 1).

There are some intriguing pharmacological differences in the effects of the (*R,R*)- and (*S,R*)-fenoterol pair relative to the (*R,R*)- and (*S,R*)-methoxyfenoterol pair in cardiomyocytes. In particular, (*R,R*)- and (*S,R*)-methoxyfenoterol are similarly less efficient at activating  $G_s\alpha$  compared with (*R,R*)-fenoterol and also do not significantly couple to  $G_i\alpha_2$ . Moreover, (*R,R*)- and (*S,R*)-methoxyfenoterol are more efficacious at activating  $G_i\alpha_3$  compared with the corresponding (*R,R*)- and (*S,R*)-fenoterol stereoisomers. Pertussis toxin only slightly shifts the contraction concentration-response curve for (*R,R*)-methoxyfenoterol to the left because coupling to  $G_s\alpha$  predominates coupling to  $G_i\alpha_2$ . This is not the case for both *S,R* derivatives, which, therefore, show distinct pertussis toxin sensitivity of the contractility. Thus, ligand stereoisomers may possess complex structure/activity relationships with respect to efficacy of G-protein activation that cannot readily be deduced from routine receptor affinity measurements (Jozwiak et al., 2007).

Viewed as a whole, the major contribution of the work by Woo et al. (2009) is to demonstrate ligand stereoisomer-specific activation of various G-protein isoforms that most likely results from stereoisomer-specific GPCR conformations. It is important to note that Woo et al. (2009) conducted their studies with isolated rat cardiomyocytes (i.e., a cell system that can be considered physiologically highly relevant). In support of the concept developed in this study are previous data from our laboratory using a recombinant expression system. In particular, the potencies and efficacies of a series of “standard” experimental  $\beta_2$ AR (partial) agonists [(–)-isoproterenol, salbutamol, dobutamine, (–)-ephedrine, and dichloroisoproterenol in order of decreasing efficacy] at  $\beta_2$ AR- $G_i\alpha$  fusion proteins are quite substantially different from the corresponding parameters at  $\beta_2$ AR- $G_s\alpha$  fusion proteins as assessed in the [ $^{35}$ S]guanosine-5'-[ $\gamma$ -thio]triphosphate binding assay (Wenzel-Seifert and Seifert, 2000). However, in our previous study, we missed the unique opportunity to dissect differences in G-protein coupling of ligand stereoisomers because we deemed this possibility as too unlikely, trying to “focus” our study on the supposedly “important” ligands. This is an excellent example of how wrong a priori probability assumptions can delay scientific progress for several years.

### How Does the $\beta_2$ AR Activate $G_i$ Proteins?

In addition to making an important contribution to our understanding of the molecular mechanisms of GPCR activation, the study of Woo et al. (2009) yielded an unexpected novel approach to address the controversial and very important issue of how  $\beta$ ARs activate  $G_i$ -proteins. Previous reconstitution studies with purified human  $\beta_2$ AR and turkey  $\beta$ AR showed that  $\beta$ ARs can activate  $G_i$  in terms of guanine nucleotide exchange to some extent without the apparent need for additional proteins and phosphorylation reactions (Asano et al., 1984; Cerione et al., 1985). In agreement with these data, the analysis of  $\beta_2$ AR coexpressed with  $G_i\alpha_2$  and of a  $\beta_2$ AR- $G_i\alpha_2$  fusion protein in Sf9 insect cell membranes revealed that the  $\beta_2$ AR activates  $G_i\alpha_2$  more sluggishly than classic

$G_i$ -coupled receptors such as the formyl peptide receptor (Wenzel-Seifert and Seifert, 2000). In contrast, an alternative hypothesis had proposed that  $\beta_2$ AR- $G_i$ -coupling depends on protein kinase A-mediated  $\beta_2$ AR phosphorylation (Daaka et al., 1997; Zamah et al., 2002). However, analysis of a  $\beta_2$ AR mutant devoid of protein kinase A phosphorylation sites did not support the latter hypothesis (Friedman et al., 2002). In their present study, Woo et al. (2009) found that all four fenoterol stereoisomers are similarly efficacious at stimulating protein kinase A-mediated  $\beta_2$ AR phosphorylation. The similar effects of stereoisomers on phosphorylation are in marked contrast to the differential effects of stereoisomers on activation of  $G_s\alpha$ ,  $G_i\alpha_2$  and  $G_i\alpha_3$  as assessed by photoaffinity labeling. In unpublished studies performed by one of us (R.S.), preincubation of  $\beta_2$ AR- $G_i\alpha_2$ -expressing Sf9 membranes with the catalytic subunit of protein kinase A, ATP, and  $Mg^{2+}$  had no effect on the efficiency of GPCR/G-protein coupling. In aggregate, the available data indicate that protein kinase A-mediated phosphorylation is not a *conditio sine qua non* for  $\beta_2$ AR/ $G_i$  coupling to occur.

### Interaction of Fenoterol Stereoisomers with the $\beta_2$ AR at the Molecular Level

Although the study by Woo et al. (2009) constitutes a major advance in the field of GPCR conformations, several important questions remain to be solved. Most importantly, how do the assumed (*R,R*)- and (*S,R*)-fenoterol-specific  $\beta_2$ AR conformations look like at the molecular level? The ultimate answer to this question will have to come from crystal structures of different states of the  $\beta_2$ AR bound to fenoterol stereoisomers. So far, however, only the crystal structure of the  $\beta_2$ AR bound to an inverse agonist, carazolol, could be resolved (Cherezov et al., 2007; Rosenbaum et al., 2007). Given the high conformational flexibility and instability of the  $\beta_2$ AR, it will be a formidable challenge to obtain high-resolution  $\beta_2$ AR crystals bound to fenoterol. Perhaps this goal can be accomplished by generating  $\beta_2$ AR- $G\alpha$ (peptide) crystals as has been very recently shown for rhodopsin (Scheerer et al., 2008). It is certainly feasible to obtain insights into the mechanism of action of fenoterol stereoisomers by studying all steps of the G-protein cycle with  $\beta_2$ AR- $G\alpha$  fusion proteins (Wenzel-Seifert and Seifert, 2000; Weitz and Seifert, 2008) at high sensitivity and to conduct fluorescence spectroscopy studies with purified  $\beta_2$ AR (Swaminath et al., 2004). In addition, molecular modeling of the  $\beta_2$ AR ligand binding site based on the available crystal structures is possible (Audet and Bouvier, 2008).

Although the high-resolution  $\beta_2$ AR crystal structure probably represents an inactive receptor state, docking of the fenoterol stereoisomers may provide suggestions about possible reasons for functional selectivity. Figure 2 shows the minimized complexes of the  $\beta_2$ AR with (*R,R*)- and (*S,R*)-fenoterol, respectively. Both isomers are docked in a favorable extended conformation close to an energy minimum. Assuming that the general binding mode corresponds to that of carazolol and that, in particular, the projection of the *N*-isopropyl and the *N*-1-methyl-2-phenylethyl substituent is similar, the  $\beta_2$ AR selectivity of the fenoterol and methoxyfenoterol isomers may be based on an H bond of the oxygen in *para* position with the imidazolyl-NH of His-93 in TM2 ( $\beta_1$ AR: Ile). However, the *para*-hydroxy group of the fenoterol isomers can form a second H bond with the backbone of




Cys-191 in E2. This may account for the higher potency of (*R,R*)-fenoterol compared with (*R,R*)-methoxyfenoterol. The *p*-hydroxyphenyl ring of both fenoterol isomers is perpendicularly arranged with respect to the indole moiety of Trp-109 (TM3). Back-folding of the aralkyl group onto Tyr-308 (TM7),

such as that suggested from CoMFA results (Jozwiak et al., 2007) and modeling (Audet and Bouvier, 2008; for bucindolol), is not likely in the case of the fenoterol derivatives as a result of sterical hindrance in the new  $\beta_2$ AR structure. The models in Fig. 2 are also consistent with the stereoselectivity at the C1 atom of *N*-1-methyl-2-phenylethyl substituted derivatives (Jozwiak et al., 2007) because, in the eutomer *R* configuration, the methyl group may form direct van der Waals contacts with the side chains of Trp-109 and Thr-110 in TM3.

In the case of *R,R*-fenoterol, the ethanolamine moiety is involved in a distinct network of hydrogen bonds and ionic interactions with the  $\beta_2$ AR (Fig. 2A). The protonated amine forms a salt bridge with Asp-113 (TM3) and a charge-assisted H bond with the side chain oxygen of Asn-312 (TM7). The hydroxy group may interact with the  $\beta_2$ AR via two H bonds, one as donor for Asp-113 (charge-assisted), and another one as acceptor for the side-chain amide of Asn-312. The phenylethyl moiety closely fits into a hydrophobic pocket consisting of Val-114 and Val-117 (TM3), Phe-193 (E2), and Trp-286, Phe-289, and Phe-290 (TM6). Rotameric changes of Trp-286 are believed to induce the “toggle switch” for receptor activation (Schwartz et al., 2006). The *meta*-hydroxy groups form H bonds with Ser-204 and Ser-207, respectively, in TM5. Both serines are critical for catecholamine binding and  $\beta_2$ AR activation (Strader et al., 1989).

In summary, the model in Fig. 2A suggests a very tight binding of (*R,R*)-fenoterol to the  $\beta_2$ AR which is in particular based on seven hydrogen bonds. (*S,R*)-fenoterol can principally bind in a similar mode and conformation (see Fig. 2B). However, the interactions with the  $\beta_2$ AR are weaker compared with the *R,R* stereoisomer because the orientation of the OH group does not enable the H bonds with Asp-113 and the amide NH<sub>2</sub> of Asn-312 (instead, an H bond with the side-chain oxygen of this asparagine is possible). In the dimeric *S* configuration, the hydroxy group is projected onto the phenyl ring of Phe-289. One *meta*-OH substituent forms an H bond with Ser-203 in place of that of the *R,R* isomer with Ser-204. The minimization has shifted the phenethanolamine moiety of (*S,R*)-fenoterol by up to 1 Å compared with its position in the  $\beta_2$ AR-(*R,R*)-fenoterol complex, indicating greater flexibility as a result of lacking interactions. This phenomenon should be further analyzed by molecular dynamics simulations. To suggest a completely different binding mode of both fenoterol isomers (e.g., a reverse fit of the phenyl moieties in the case of the *S,R*-derivative) would be rather bold, because the stereoselectivity of the second chiral center is generally the same, independent of the configuration of the OH group.

Taken together, the models indicate possible reasons for the functional selectivity of fenoterol and methoxyfenoterol stereoisomers. It seems that deviations from the “normal” predominant G<sub>s</sub> coupling of the  $\beta_2$ AR and more promiscuity with respect to different G protein species just occur if certain interactions cannot be formed. Then the ligand-receptor complex has more degrees of conformational freedom than in the case of a tightly bound structure [such as (*R,R*)-fenoterol]. The higher flexibility enables the generation of a greater number of alternative conformations from which some may indeed represent “ligand-specific active receptor states,” interacting more or less selectively with G<sub>s</sub>α, G<sub>i</sub>α<sub>2</sub>, or G<sub>i</sub>α<sub>3</sub>. That is, ligand-specific inactive GPCR conformations are not



**Fig. 2.** Model of the interaction of (*R,R*)-fenoterol and (*S,R*)-fenoterol with the  $\beta_2$ AR based on the  $\beta_2$ AR crystal structure (Protein Data Base ID 2RH1). The ligands were manually docked and the complexes were in turn minimized with the Amber-FF99 ( $\beta_2$ AR with fixed ligand) and the Tripos force field (ligands and a “hot” receptor region of amino acids up to 6 Å distant). Modeling was performed with SYBYL 7.3 (Tripos, St. Louis, MO). Both panels show the side chains and C $\alpha$  atoms of all amino acids within 3 Å around the ligands (in addition, Tyr-308 and a backbone sequence in E2) as sticks and the C $\alpha$  trace of the TM regions as lines. The backbone, the carbon, and some essential hydrogen atoms of the amino acids are individually drawn in spectral colors: TM2, orange; TM3, yellow; E2, cyan; TM5, greenblue; TM6, blue; TM7, purple. Nitrogen, blue; oxygen, red; sulfur, yellow. Atoms of the  $\beta_2$ AR suggested to be involved in H bonds with the ligand are marked as balls. A, docking of (*R,R*)-fenoterol (ball-and-stick model with gray carbon and essential hydrogen atoms). B, docking of (*S,R*)-fenoterol (ball-and-stick model with pink carbon and essential hydrogen atoms). For comparison, the scaffold of (*R,R*)-fenoterol (stick model, gray C atoms) from A is also drawn, based on a superposition of all binding site atoms of both models (root-mean-square deviation 0.47 Å).

a necessary condition for promiscuous G protein coupling. This hypothesis must be further substantiated by molecular dynamics simulations and can be verified only by crystal structures of active GPCR states. A first milestone on this long way has been very recently set by the release of an opsin structure in its G-protein-interacting conformation (Scheerer et al., 2008), showing an outward tilt of TM6 and a pairing of TMs 5 and 6.

### Some Future Studies

(*R,R*)-Fenoterol is a  $G_s$ -selective full  $\beta_2$ AR agonist, whereas (*S,R*)-fenoterol is a partial  $\beta_2$ AR agonist with respect to  $G_s$ -activation and a full agonist with respect to  $G_i\alpha_2$ -activation (Fig. 1). It will be important to develop  $G_i$ -selective  $\beta_2$ AR agonists to learn more about the as-yet-elusive (patho)-physiological relevance of the  $\beta_2$ AR-activated  $G_i$  pathway in cardiomyocytes and other systems such as bronchial smooth muscle cells. This will not be trivial, because to this end, the potency of most  $\beta_2$ AR agonists for the  $G_i$  pathway is considerably lower than for the  $G_s$  pathway (Wenzel-Seifert and Seifert, 2000). Moreover, high potency of  $G_i$ -selective  $\beta_2$ AR agonists would be most welcome to avoid potential ligand interactions with the  $\beta_1$ AR and  $\beta_3$ AR. Future studies will also have to address the question of whether in addition to  $G_s$  and  $G_i$ , fenoterol stereoisomers differentially activate pertussis toxin-insensitive  $G_q$ -proteins that mediate phospholipase C activation. The necessity for such studies comes from the finding that the stimulatory effects of the four fenoterol stereoisomers examined exhibit striking differential and partial pertussis toxin-insensitivity, which is not discussed in the article by Woo et al. (2009). Previous studies from our laboratory have shown that the pharmacological profile of the  $\beta_2$ AR coupled to  $G_q$ -proteins differs from the profile of the  $G_s$ - and  $G_i$ -coupled  $\beta_2$ AR, although  $G_q$ -coupling was rather poor in our hands (Wenzel-Seifert and Seifert, 2000). It will also be necessary to study the impact of G-protein  $\beta_x\gamma_y$ -complexes on  $G\alpha$ -selectivity of fenoterol stereoisomers. In particular, the stereoisomers differ remarkably from each other in terms of  $G_s\alpha$  activation, but they are quite similar in terms of  $\beta_2$ AR phosphorylation. An explanation for this discrepancy could be the recruitment of different  $G\beta_x\gamma_y$ -complexes by the various stereoisomers, compensating for the differences observed with respect to  $G_s\alpha$  activation.

The current study by Woo et al. (2009) focuses on efficacies of fenoterol stereoisomers with regard to the various parameters. Although this is sufficient to support the main hypothesis of the article, future studies should also carefully examine agonist potencies, because it is very possible that a given ligand possesses not only multiple efficacies but also multiple affinities for the various receptor conformations, depending on the specific parameter analyzed. These studies will bring us a step closer to the goal of achieving ligand-specific activation of  $G\alpha$ -protein subtypes. Multiple parameter-dependent affinities/potencies of a given ligand for the  $\beta_2$ AR have been observed before (Seifert et al., 1999, 2001; Weigl and Seifert, 2008).

Elegant studies with opioid receptors have shown that various ligands differ from each other in their membrane and cell compartment trafficking (Hanyaloglu and von Zastrow, 2008). Thus, it is conceivable that fenoterol stereoisomers show differences in  $\beta_2$ AR trafficking as well. In particular, resistance of fenoterol/ $\beta_2$ AR complexes to desensitization

and internalization may occur because long-term treatment with fenoterol in a heart failure model is not associated with a loss of efficacy (Ahmet et al., 2008). In this context, it will also be interesting to examine the effects of fenoterol stereoisomers on long-term effects such as gene expression using the microarray technique.

The study by Woo et al. (2009) has important implications for future agonist screening programs in the pharmaceutical industry. It is clear that any drug development program dealing with stereoisomers should not only search for "more active" high-potency eutomers but also for "less active" low-potency distomers (Fig. 1). Moreover, it is prudent to study at least two independent signals for each GPCR, preferably mediated by different G-proteins. And even for GPCRs that couple to only one cognate G-protein, it is advisable to determine several signals at various steps of the G-protein cycle because differences of ligand potencies and efficacies for the various parameters within the cycle can be substantial, even if endogenous agonists are considered (Seifert et al., 1999, 2001; Weigl and Seifert, 2008). On first glance, this may sound like bad news because initially, a drug development program will become more complicated, expensive, and time-consuming. On second glance, however, the return may be novel interesting drugs that would have been missed using standard approaches aimed only at high-potency ligands and measuring only one signal. We missed such a great opportunity in our laboratory several years ago (Wenzel-Seifert and Seifert, 2000).

### Clinical Implications

The present study has important clinical implications. In particular, fenoterol is widely used for the treatment of acute asthma attacks, and uncritical use of racemic fenoterol is associated with increased mortality of patients with asthma (Jalpa, 2008). Thus, clinical studies will have to answer the question of whether specific fenoterol stereoisomers, through their unique pattern of G-protein activation, possess clinically relevant differences in terms of therapeutic efficacy and toxicity. Along the same line, albuterol possesses a chirality center (Boulton and Fawcett, 2002; Broadley, 2006). However, to this end, it is unclear whether levalbuterol exhibits any relevant clinical advantages compared with racemic albuterol. Although additional clinical studies on this topic are certainly warranted, it is also important to characterize levalbuterol and dexalbuterol in detail at the molecular and cellular levels, because so far, most mechanistic studies have been performed only with racemic albuterol (Seifert et al., 1999, 2001; Wenzel-Seifert and Seifert, 2000). The reason for this situation is simply the limited stereoisomer availability to the pharmacological community.

Another potential application of  $\beta_2$ AR agonists is the treatment of heart failure as adjunct to  $\beta_1$ AR antagonists. In particular, in a rat model of dilated cardiomyopathy, long-term treatment with racemic fenoterol enhances the beneficial effects of  $\beta_1$ AR blockade with metoprolol (Ahmet et al., 2008). Again, it will be interesting to examine the effects of fenoterol stereoisomers in this model. The efficacy of the agonist in this long-term treatment setting points to the lack of relevant desensitization.

Finally, we have recently shown that the endogenous  $\beta_2$ AR agonists (–)-epinephrine and (–)-norepinephrine interact differently with the  $\beta_2$ AR and  $\beta_1$ AR coupled to either of the



two G<sub>s</sub>α splice variants (Weitl and Seifert, 2008). Both catecholamines are used clinically in life-threatening conditions such as cardiac arrest and septic shock. The careful analysis of the corresponding (+)-enantiomers of catecholamines may yield drugs with improved clinical properties relative to the naturally occurring (–)-enantiomers. This possibility has not yet been explored at all. In this context, it will also be very interesting and important to determine whether fenoterol stereoisomers interact differentially with the various human β<sub>2</sub>AR polymorphic isoforms (Brodde, 2008).

## Conclusions

The current study by Woo et al. (2009) corroborates the concept of ligand-specific GPCR conformations, resulting in differential G-protein activation or, in more general terms, functional selectivity. Ligand stereoisomers are important experimental tools to examine mechanisms of GPCR activation and signal transduction pathways. The present study should encourage pharmacologists to systematically examine the “more active” eutomer and the “less active” distomer of a given ligand and not focus only on more readily available racemic ligands or “eutomers.” We anticipate that analysis of ligand stereoisomers with modern pharmacological and biophysical methods will be a success and yield important data, ultimately improving clinical drug therapy and reducing drug toxicity.

## Acknowledgments

R.S. would like to thank Dr. Brian Kobilka (Stanford University, Stanford, CA) for many stimulating discussions on mechanisms of β<sub>2</sub>AR activation and Dr. Katharina Wenzel-Seifert for fruitful experimental collaboration on the β<sub>2</sub>AR.

## References

- Ahmet I, Krawczyk M, Zhu W, Woo AY, Morrell C, Poosala S, Xiao RP, Lakatta EG, and Talan MI (2008) Cardioprotective and survival benefits of long-term combined therapy with β<sub>2</sub> adrenoceptor (AR) agonist and β<sub>1</sub> AR blocker in dilated cardiomyopathy postmyocardial infarction. *J Pharmacol Exp Ther* **325**:491–499.
- Asano T, Katada T, Gilman AG, and Ross EM (1984) Activation of the inhibitory GTP-binding protein of adenylate cyclase, G<sub>i</sub>, by β-adrenergic receptors reconstituted in phospholipid vesicles. *J Biol Chem* **259**:9351–9354.
- Audet M and Bouvier M (2008) Insights into signaling from the β<sub>2</sub>-adrenergic receptor structure. *Nat Chem Biol* **4**:397–403.
- Boulton DW and Fawcett JP (2002) β<sub>2</sub>-Agonist eutomers: a rational option for the treatment of asthma? *Am J Respir Med* **115**:305–311.
- Broadley KJ (2006) β-Adrenoceptor responses of the airways: for better or worse? *Eur J Pharmacol* **533**:15–27.
- Brodde OE (2008) β-1 and β-2 Adrenoceptor polymorphisms: functional importance, impact on cardiovascular diseases and drug responses. *Pharmacol Ther* **117**:1–29.
- Cerione RA, Staniszewski C, Benovic JL, Lefkowitz RJ, Caron MG, Gierschik P, Somers R, Spiegel AM, Codina J, and Birnbaumer L (1985) Specificity of the functional interactions of the β-adrenergic receptor and rhodopsin with guanine nucleotide regulatory proteins reconstituted in phospholipid vesicles. *J Biol Chem* **260**:1493–1500.
- Cherezov V, Rosenbaum DM, Hanson MA, Rasmussen SG, Thian FS, Kobilka TS, Choi HJ, Kuhn P, Weis WI, Kobilka BK, et al. (2007) High-resolution crystal structure of an engineered human β<sub>2</sub>-adrenergic G protein-coupled receptor. *Science* **318**:1258–1265.
- Cushny AR (1908) The action of optical isomers. III. Adrenalin. *J Physiol* **37**:130–138.
- Daaka Y, Luttrell LM, and Lefkowitz RJ (1997) Switching of the coupling of the β<sub>2</sub>-adrenergic receptor to different G proteins by protein kinase A. *Nature* **390**:88–91.
- Friedman J, Babu B, and Clark RB (2002) β<sub>2</sub>-Adrenergic receptor lacking the cyclic AMP-dependent protein kinase consensus sites fully activates extracellular signal-regulated kinase 1/2 in human embryonic kidney 293 cells: lack of evidence for G<sub>i</sub>/G<sub>o</sub> switching. *Mol Pharmacol* **62**:1094–1102.
- Galandrin S, Oligny-Longpré G, and Bouvier M (2007) The elusive nature of drug efficacy: implications for drug discovery. *Trends Pharmacol Sci* **28**:423–430.
- Gether U and Kobilka BK (1998) G protein-coupled receptors. II. Mechanism of activation. *J Biol Chem* **273**:17979–17982.
- Hanyaloglu AC and von Zastrow M (2008) Regulation of GPCRs by endocytic membrane trafficking and its potential implications. *Annu Rev Pharmacol Toxicol* **48**:537–568.
- Jalba MS (2008) Three generations of ongoing controversies concerning the use of short-acting β-agonist therapy in asthma: a review. *J Asthma* **45**:9–18.
- Jansson CC, Kukkonen JP, Näsman J, Huifang G, Wurster S, Virtanen R, Savola JM, Cockcroft V, and Akerman KE (1998) Protean agonism at α<sub>2A</sub>-adrenoceptors. *Mol Pharmacol* **53**:963–968.
- Jozwiak K, Khalid C, Tanga MJ, Berzetei-Gurske I, Jimenez L, Kozocas JA, Woo A, Zhu W, Xiao RP, Abernethy DR, et al. (2007) Comparative molecular field analysis of the binding of the stereoisomers of fenoterol and fenoterol derivatives to the β<sub>2</sub> adrenergic receptor. *J Med Chem* **50**:2903–2915.
- Kenakin T (2007) Functional selectivity through protean and biased agonism. Who steers the ship? *Mol Pharmacol* **72**:1393–1401.
- Kim MY, Salman K, and Patil PN (1981) α-Adrenoceptor-related dissociation constants and intrinsic efficacies of stereoisomers of epinephrine. *Blood Vessels* **18**:145–152.
- Kobilka BK and Deupi X (2007) Conformational complexity of G-protein-coupled receptors. *Trends Pharmacol Sci* **28**:397–406.
- Lohse MJ, Nikolaev VO, Hein P, Hoffmann C, Vilardaga JP, and Bünemann M (2008) Optical techniques to analyze real-time activation and signaling of G-protein-coupled receptors. *Trends Pharmacol Sci* **29**:159–165.
- Milligan G, Parenty G, Stoddart LA, and Lane JR (2007) Novel pharmacological applications of G-protein-coupled receptor-G protein fusions. *Curr Opin Pharmacol* **7**:521–526.
- Neubig RR (2007) Missing links: mechanisms of protean agonism. *Mol Pharmacol* **71**:1200–1202.
- Patil PN, Li C, Kumari V, and Hieble JP (2008) Analysis of efficacy of chiral adrenergic agonists. *Chirality* **20**:529–543.
- Patil PN, Eraundorfer P, and Dutta PK (1996) Stereoselective modification of circular dichroism spectra of rat lung β-adrenoceptor protein preparation by enantiomers of epinephrine. *Chirality* **8**:463–465.
- Perez DM and Karnik SS (2005) Multiple signaling states of G-protein-coupled receptors. *Pharmacol Rev* **57**:147–161.
- Rohrer DK and Kobilka BK (1998) Insights from *in vivo* modification of adrenergic receptor gene expression. *Annu Rev Pharmacol Toxicol* **38**:351–373.
- Rosenbaum DM, Cherezov V, Hanson MA, Rasmussen SG, Thian FS, Kobilka TS, Choi HJ, Yao XJ, Weis WI, Stevens RC, et al. (2007) GPCR engineering yields high-resolution structural insights into β<sub>2</sub>-adrenergic receptor function. *Science* **318**:1266–1273.
- Scheerer P, Park JH, Hildebrand PW, Kim YJ, Krauss N, Choe HW, Hofmann KP, and Ernst OP (2008) Crystal structure of opsin in its G-protein-interacting conformation. *Nature* **455**:497–502.
- Schwartz TW, Primur TM, Holst B, Rosenkilde MM, and Elling CE (2006) Molecular mechanism of 7TM receptor activation—a global toggle switch model. *Annu Rev Pharmacol Toxicol* **46**:481–519.
- Seifert R and Wenzel-Seifert K (2002) Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors. *Naunyn Schmiedeberg Arch Pharmacol* **366**:381–416.
- Seifert R, Gether U, Wenzel-Seifert K, and Kobilka BK (1999) Effects of guanine, inosine, and xanthine nucleotides on β<sub>2</sub>-adrenergic receptor/G<sub>s</sub> interactions: evidence for multiple receptor conformations. *Mol Pharmacol* **56**:348–358.
- Seifert R, Wenzel-Seifert K, Gether U, and Kobilka BK (2001) Functional differences between full and partial agonists: evidence for ligand-specific receptor conformations. *J Pharmacol Exp Ther* **297**:1218–1226.
- Strader CD, Candelore MR, Hill WS, Sigal IS, and Dixon RA (1989) Identification of two serine residues involved in agonist activation of the beta-adrenergic receptor. *J Biol Chem* **264**:13572–13578.
- Strasser A, Striegl B, Wittmann HJ, and Seifert R (2008) Pharmacological profile of histaprodifens at four recombinant histamine H<sub>1</sub> receptor species isoforms. *J Pharmacol Exp Ther* **324**:60–71.
- Swaminath G, Xiang Y, Lee TW, Steenhuis J, Parnot C, and Kobilka BK (2004) Sequential binding of agonists to the β<sub>2</sub> adrenoceptor. Kinetic evidence for intermediate conformational states. *J Biol Chem* **279**:686–691.
- Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, Javitch JA, Roth BL, Christopoulos A, Sexton PM, et al. (2007) Functional selectivity and classical concepts of quantitative pharmacology. *J Pharmacol Exp Ther* **320**:1–13.
- Weitl N and Seifert R (2008) Distinct interactions of human β<sub>1</sub>- and β<sub>2</sub>-adrenoceptors with isoproterenol, epinephrine, norepinephrine and dopamine. *J Pharmacol Exp Ther* **327**:760–769.
- Wenzel-Seifert K and Seifert R (2000) Molecular analysis of β<sub>2</sub>-adrenoceptor coupling to G<sub>s</sub>-, G<sub>i</sub>-, and G<sub>o</sub>-proteins. *Mol Pharmacol* **58**:954–966.
- Woo AYH, Wang TB, Zeng X, Zhu W, Abernethy DR, Wainer IW and Xiao RP (2009) Stereochemistry of an agonist determines coupling preference of β<sub>2</sub>-adrenoceptor to different G proteins in cardiomyocytes. *Mol Pharmacol* **75**:158–165.
- Xiao RP, Ji X, and Lakatta EG (1995) Functional coupling of the β<sub>2</sub>-adrenoceptor to a pertussis toxin-sensitive G protein in cardiac myocytes. *Mol Pharmacol* **47**:322–329.
- Xiao RP, Zhang SJ, Chakir K, Avdonin P, Zhu W, Bond RA, Balke CW, Lakatta EG, and Cheng H (2003) Enhanced G<sub>i</sub> signaling selectively negates β<sub>2</sub>-adrenergic receptor (AR)- but not β<sub>1</sub>-AR-mediated positive inotropic effect in myocytes from failing rat hearts. *Circulation* **108**:1633–1639.
- Zamah AM, Delahunty M, Luttrell LM, and Lefkowitz RJ (2002) Protein kinase A-mediated phosphorylation of the β<sub>2</sub>-adrenergic receptor regulates its coupling to G<sub>s</sub> and G<sub>i</sub>. Demonstration in a reconstituted system. *J Biol Chem* **277**:31249–31256.

**Address correspondence to:** Dr. Roland Seifert, Department of Pharmacology, Medical School of Hannover, Carl-Neuberg-Straße 1, D-30625 Hannover, Germany. E-mail: seifert.roland@mh-hannover.de